Fabiflu in COVID-19 As we know the vaccine is still a long distance away and no sign of the coronavirus infections slowing down in the country , homegrown pharmaceutical companies have been given permission to launch generic versions of Remdesivir and Favipiravir , anti-viral drugs that have shown promise in treating Covid-19 patients. Glenmark pharmaceuticles has launched favipiravir under the brand name FabiFlu for treatment of mild to moderate cases of Covid-19 , cipla and hetero labs have received approvals from the Drug Controller General of India to launch generic versions of Remedesivir under the names Cipremi and Covifor respectively. While medical experts have cautioned against seeing these potential drugs as a "magic bullet" against the deadly virus , they can be helpful in reducing the viral load as India continues to post new record highs in infection on a daily basis. Remedesivir and Favipiravir are two of the 130 under experimentation drugs worldwide to treat c...
Knowledge about the medical science and physiotherapeutic articles and news. In this you will get some differentiations and new treatments about physiotherapy and also some diseases.